Study design
Breast cancer
BREAST CANCER, BLIND
This study was a randomized, double blind, double dummy, placebo-controlled trial conducted at Division of Cardiology, Chiang Mai University hospital, Thailand. Breast cancer patients scheduled to receive doxorubicin were referred from primary physician to determine their eligibility to the trial. The study protocol was approved by the Ethics Committee of Faculty of Medicine, Chiang Mai University (Study Code: MED-2563-07001) and registered at Thai Clinical Trials Registry (TCTR), identification number TCTR20200116007, first trial registration 16/01/2020. The study complied with the Declaration of Helsinki. Written informed consent was obtained from each patient.